We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App

C. Difficile Colonization Among Children in Resource-Limited Settings

By LabMedica International staff writers
Posted on 02 Mar 2022
Print article
Image: A medical illustration of Clostridioides difficile bacteria (Photo courtesy of Jennifer Oosthuizen, MA)
Image: A medical illustration of Clostridioides difficile bacteria (Photo courtesy of Jennifer Oosthuizen, MA)

This study describes the epidemiology and risk factors for colonization among children in the etiology, risk factors, and interactions of enteric infections and malnutrition. Also explored was whether C. difficile detection contributed to longer-term health outcomes.

Clostridioides difficile
is a bacterium that causes severe diarrhea and colitis. It’s estimated to cause almost half a million infections in the USA each year. About 1 in 6 patients who get C. diff will get it again in the subsequent 2-8 weeks. One in 11 people over age 65 diagnosed with a healthcare-associated C. diff infection die within one month.

High rates of C. difficile colonization have been documented among infants in resource sufficient settings, where C. difficile infection (CDI) rates can be as high as 90% among hospitalized neonates. Colonization decreases with increasing age until age two when rates start to mirror healthy adults. Some studies have indicated that C. difficile may be more prevalent than rotavirus or Cryptosporidium in children presenting with diarrhea to the hospital.

Infectious Disease specialists at The University of Virginia School of Medicine (Charlottesville, VA, USA) conducted a study at eight sites: Dhaka, Bangladesh; Fortaleza, Brazil; Vellore, India; Bhaktapur, Nepal; Loreto, Peru; Naushero Feroze, Pakistan; Venda, South Africa; and Haydom, Tanzania. The study ran from November 2009 through February 2014. The team tested 41,354 monthly non-diarrheal and diarrheal stools for C. difficile toxin genes (tcdA and tcdB) using quantitative polymerase chain reaction (qPCR) in 1,715 children from birth to age two years.

The QIAmp Fast DNA Stool Mini Kit (Qiagen, Venlo, The Netherlands) was used to extract total nucleic acid from the stool specimens. TaqMan Array Cards (TAC) were developed to detect 29 enteropathogens via qPCR using AgPath One Step Realtime PCR kit (Thermo Fisher Scientific, Waltham, MA, USA). The qPCR assays targeting C. difficile tcdA (enterotoxin) and tcdB (cytotoxin) genes were validated on the TaqMan Array platform, demonstrating 100% sensitivity and 100% specificity on clinical specimens using a secondary real time PCR as confirmation.

Monthly stool samples were tested for myeloperoxidase (MPO; measured in ng/m), neopterin (NEO; measured in nmol/L), and α-1-antitrypsin (AAT; measured in mg/g) and analyzed on the logarithmic scale. Serum α-1-acid glycoprotein was measured at months 7, 15, and 24 (AGP; measured in mg/dL). Lactulose/mannitol excretion ratios (LMR) were measured in urine at 3, 6, 9, and 15 months. Plasma zinc and retinol were measured at 7, 15, and 24 months.

The scientists reported that the prevalence of C. difficile detection was lower in diarrheal (2.2%; n= 151/6,731) compared to non-diarrheal stools (6.1%; n= 2106/34,623). By 24 months of age, the cumulative incidence of C. difficile varied widely by site, ranging from 17.9% (n=44; Pakistan) to 76.3% (n=148; Peru) of children having at least one positive stool. Only Bangladesh and Pakistan had seasonal differences in C. difficile detection. Female gender (adjusted risk ratio (aRR):1.18), cephalosporin use in the past 15 days (aRR: 1.73), and treated water (aRR: 1.24) were risk factors for C. difficile positivity. C. difficile carriage was significantly associated with elevated fecal myeloperoxidase, neopterin, and α-1-antitrypsin, but no associations were found between C. difficile and child growth at 24 months of age.

The authors concluded that C. difficile colonization among children ages 0-2 years was variable across low-resource settings. Significant elevation of intestinal inflammation and barrier disruption markers associated with C. difficile detection suggests subclinical impact of colonization. The study was published on February 09, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
University of Virginia School of Medicine 
Thermo Fisher Scientific

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
hCG Whole Blood Pregnancy Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Motorized Pipette Controller

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: Made-to-order diagnostic tests may soon be on the horizon (Photo courtesy of McGill University)

Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible

Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.